List view / Grid view

Sanofi

 

news

Journal of Clinical Oncology publishes Phase III results of ZALTRAP® (aflibercept) VELOUR study

8 October 2012 | By

Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that detailed results from the pivotal Phase III VELOUR study evaluating ZALTRAP® (aflibercept) Injection for Intravenous Infusion for the treatment of patients with previously treated metastatic colorectal cancer were published in the October 2012 edition of the Journal of Clinical Oncology (JCO).

news

New data from ORIGIN

5 October 2012 | By Sanofi

New data from ORIGIN shows Lantus® use is about 3 times more likely to achieve and sustain target HbA1c vs. standard care over 5 years in the study population...